Evidence map›Paper›PMID 28585092›Full record

ArticleMycorrhiza2017

Rhizophagus irregularis MUCL 41833 transitorily reduces tomato bacterial wilt incidence caused by Ralstonia solanacearum under in vitro conditions.

Marie Chave, Patrice Crozilhac, Péninna Deberdt, Katia Plouznikoff, Stéphane Declerck

Abstract read
PubMed Publisher
In one paragraph

Article in Mycorrhiza, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marie ChaveASTRO Agrosystèmes tropicaux, INRA, 97170, Petit-Bourg, Guadeloupe, France. marie.chave@inra.fr.ORCID http://orcid.org/0000-0003-4911-348X
Patrice CrozilhacEarth and Life Institute, Mycology, Université catholique de Louvain (UCL), Croix du Sud 2, bte L7.05.06, 1348, Louvain-la-Neuve, Belgium.
Péninna DeberdtCIRAD, UPR HORTSYS, Campus Agro-Environnemental Caraïbe, F-97285, Le Lamentin, Martinique, France.
Katia PlouznikoffEarth and Life Institute, Mycology, Université catholique de Louvain (UCL), Croix du Sud 2, bte L7.05.06, 1348, Louvain-la-Neuve, Belgium.
Stéphane DeclerckEarth and Life Institute, Mycology, Université catholique de Louvain (UCL), Croix du Sud 2, bte L7.05.06, 1348, Louvain-la-Neuve, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial wilt caused by Ralstonia solanacearum is one of the world's most important soil-borne plant diseases. In Martinique, French West Indies, a highly virulent new pathogenic variant of this bacterium (phylotype IIB/4NPB) severely impacts tomato production. Here we report on the effect of R. solanacearum CFBP 6783, classified in phytotype IIB/4NPB, on tomato plantlets grown under strict in vitro culture conditions in the presence or absence of the arbuscular mycorrhizal fungus Rhizophagus irregularis MUCL 41833. A mycelium donor plant (i.e. Crotalaria spectabilis) was used for rapid, uniform mycorrhization of tomato plantlets that were subsequently infected by the bacterium. Bacterial wilt was significantly delayed and the incidence of the disease consequently reduced in the mycorrhizal tomato plantlets. Conversely, R. solanacearum did not affect root colonization by the AMF within the 16 days of the experiment. These results suggested that the mycorrhizal fungus was able to reduce bacterial wilt symptoms, probably by eliciting defence mechanisms in the plant.

Indexed as

GlomeromycotaMycorrhizaePlant DiseasesRalstonia solanacearumSolanum lycopersicumBacterial wiltBiocontrolRalstonia solanacearumRhizophagus irregularisTomato

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.